{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:35:02Z","timestamp":1790681702378,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"am","delay-in-days":393,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.bulcan.2018.12.007","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T10:06:37Z","timestamp":1547201197000},"page":"37-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Les immunoth\u00e9rapies sp\u00e9cifiques dans le traitement des cancers"],"prefix":"10.1016","volume":"106","author":[{"given":"H\u00e9l\u00e8ne","family":"Denis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Davoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Bermudez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghislain","family":"Grosjean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Ifrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Negellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2018.12.007_bib0170","unstructured":"Institut national du cancer. Immunoth\u00e9rapie: mode d\u2019action - Th\u00e9rapies cibl\u00e9es et immunoth\u00e9rapie sp\u00e9cifique. [Internet]. 2017. Disponible sur: http:\/\/www.e-cancer.fr\/Patients-et-proches\/Se-faire-soigner\/Traitements\/Therapies-ciblees-et-immunotherapie-specifique\/Immunotherapie-mode-d-action."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0175","unstructured":"ClinicalTrials.gov [Internet]. Disponible sur: https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0180","unstructured":"U.S. Food and drug administration. FDA Alerts Healthcare Professionals and Oncology Clinical Investigators about Two Clinical Trials on Hold Evaluating KEYTRUDA\u00ae (pembrolizumab) in Patients with Multiple Myeloma [Internet]. 09\/2017. Disponible sur: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm574305.htm."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0185","unstructured":"European Medicines Agency. Find medicine - Yervoy [Internet]. Disponible sur\u00a0: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/002213\/human_med_001465.jsp&mid=WC0b01ac058001d124."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0190","unstructured":"European Medicines Agency. Find medicine - Tecentriq [Internet]. Disponible sur\u00a0: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/004143\/human_med_002166.jsp&mid=WC0b01ac058001d124."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0195","unstructured":"European Medicines Agency. Find medicine - Opdivo [Internet]. Disponible sur\u00a0: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003985\/human_med_001876.jsp&mid=WC0b01ac058001d124."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0200","unstructured":"European Medicines Agency. Find medicine - Keytruda [Internet]. Disponible sur\u00a0: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003820\/human_med_001886.jsp&mid=WC0b01ac058001d124."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0205","unstructured":"European Medicines Agency. Find medicine - Bavencio [Internet]. Disponible sur\u00a0: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/004338\/human_med_002157.jsp&mid=WC0b01ac058001d124."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0210","unstructured":"U.S. Food and drug administration. Approved Products - YESCARTA (axicabtagene ciloleucel) [Internet]. 2018. Disponible sur\u00a0: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/ucm581222.htm."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0215","unstructured":"U.S. Food and drug administration. Approved Products - KYMRIAH (tisagenlecleucel) [Internet]. 2018. Disponible sur\u00a0: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/CellularGeneTherapyProducts\/ApprovedProducts\/ucm573706.htm."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0220","unstructured":"U.S. Food and drug administration. Keytruda label [Internet]. Disponible sur\u00a0: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125514s031lbl.pdf."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0225","unstructured":"ASCO CAR T-Cell Immunotherapy Named Advance of the Year in Annual ASCO Report [Internet]. ASCO. 2018. Disponible sur\u00a0: https:\/\/www.asco.org\/about-asco\/press-center\/news-releases\/car-t-cell-immunotherapy-named-advance-year-annual-asco-report."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0230","unstructured":"European Medicines Agency. Chimeric antigen receptor (CAR) T-cell therapy registries workshop [Internet]. 2018. Disponible sur\u00a0: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/events\/2018\/01\/event_detail_001569.jsp&mid=WC0b01ac058004d5c3."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0235","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - YERVOY M\u00e9lanome 1\u00e8re et 2\u00e8me ligne [Internet]. 2017. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2769366\/fr\/yervoy-melanome-1ere-et-2eme-ligne?xtmc=&xtcr=1."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0240","unstructured":"Haute Autorit\u00e9 de sant\u00e9. YERVOY (ipilimumab), anticorps monoclonal - Nouvelle indication [Internet]. 2014. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_1779495\/fr\/yervoy-ipilimumab-anticorps-monoclonal?xtmc=&xtcr=4."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0245","unstructured":"Haute Autorit\u00e9 de sant\u00e9. YERVOY - Nouveau m\u00e9dicament [Internet]. 12\/2011. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_1189034\/fr\/yervoy?xtmc=&xtcr=6."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0250","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - YERVOY [Internet]. 2013. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_1701283\/fr\/yervoy?xtmc=&xtcr=5."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0255","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Commission de la transparence - OPDIVO CBNPC non \u00e9pidermo\u00efde [Internet]. 2017. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2742286\/fr\/opdivo-cbnpc-non-epidermoide?xtmc=&xtcr=7."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0260","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - OPDIVO Carcinome \u00e0 cellules r\u00e9nales [Internet]. 2016. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2682094\/fr\/opdivo-carcinome-a-cellules-renales?xtmc=&xtcr=8."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0265","unstructured":"Haute Autorit\u00e9 de sant\u00e9. OPDIVO (nivolumab), anticorps anti-PD1 - Nouveau m\u00e9dicament [Internet]. 2016. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2639665\/fr\/opdivo-nivolumab-anticorps-anti-pd1?xtmc=&xtcr=10."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0270","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. OPDIVO (nivolumab), anticorps anti-PD1- Nouvelle indication [Internet]. 2017. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2757885\/fr\/opdivo-nivolumab-anticorps-anti-pd1?xtmc=&xtcr=2."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0275","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - OPDIVO (nivolumab), anticorps anti-PD1 [Internet]. 2016. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2612055\/fr\/opdivo-nivolumab-anticorps-anti-pd1."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0280","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - OPDIVO - m\u00e9lanome en association \u00e0 YERVOY [Internet]. 2017. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2770199\/fr\/opdivo-melanome-en-association-a-yervoy?xtmc=&xtcr=3."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0285","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - KEYTRUDA M\u00e9lanome [Internet]. 2017. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2769037\/fr\/keytruda-melanome?xtmc=&xtcr=4."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0290","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - KEYTRUDA (pembrolizumab), anticorps anti-PD1 [Internet]. 2016. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2639673\/fr\/keytruda-pembrolizumab-anticorps-anti-pd1?xtmc=&xtcr=10."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0295","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - KEYTRUDA - CBNPC 2e ligne [Internet]. 2017. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2755875\/fr\/keytruda-cbnpc-2eme-ligne?xtmc=&xtcr=5."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0300","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - KEYTRUDA - CBNPC 1\u00e8re ligne [Internet]. 2017. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2774645\/fr\/keytruda-cbnpc-1ere-ligne?xtmc=&xtcr=3."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0305","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Commission de la transparence - KEYTRUDA [Internet]. 2017. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2780761\/fr\/keytruda?xtmc=&xtcr=2."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0310","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Avis N(2016.0027\/AC\/SEESP du 16\u00a0mars 2016\u00a0du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 sur l\u2019efficience de la prise en charge par l\u2019Assurance maladie de la sp\u00e9cialit\u00e9 KEYTRUDA (pembrolizumab) dans le traitement du m\u00e9lanome avanc\u00e9 (non r\u00e9s\u00e9cable ou m\u00e9tastatique) [Internet]. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2751763\/fr\/avis-n-2016-0027\/ac\/seesp-du-16-mars-2016-du-college-de-la-haute-autorite-de-sante-sur-l-efficience-de-la-prise-en-charge-par-l-assurance-maladie-de-la-specialite-keytruda-pembrolizumab-dans-le-traitement-du-melanome-avance-non-resecable-ou-metastatique?xtmc=&xtcr=6."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0315","unstructured":"Haute Autorit\u00e9 de sant\u00e9. AVIS N(2016.0002\/AC\/SEM du 13\u00a0janvier 2016\u00a0du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 en vue de l\u2019inscription sur la liste pr\u00e9vue \u00e0 l\u2019article L.;1; 5123-2\u00a0du code de la sant\u00e9 publique de la sp\u00e9cialit\u00e9 OPDIVO (nivolumab) dans le traitement du m\u00e9lanome avanc\u00e9 (non r\u00e9s\u00e9cable ou m\u00e9tastatique) [Internet]. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2588709\/fr\/avis-n-2016-0002\/ac\/sem-du-13-janvier-2016-du-college-de-la-haute-autorite-de-sante-en-vue-de-l-inscription-sur-la-liste-prevue-a-l-article-l-5123-2-du-code-de-la-sante-publique-de-la-specialite-opdivo-nivolumab-dans-le-traitement-du-melanome-avance-non-resecable-ou-metastatique?xtmc=&xtcr=13."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0320","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Avis N(2016.0001\/AC\/SEESP du 13\u00a0janvier 2016\u00a0du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 sur l\u2019efficience de la prise en charge par l\u2019assurance maladie de la sp\u00e9cialit\u00e9 OPDIVO (nivolumab) dans le traitement du m\u00e9lanome avanc\u00e9 (non r\u00e9s\u00e9cable ou m\u00e9tastatique) [Internet]. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2751756\/fr\/avis-n-2016-0001\/ac\/seesp-du-13-janvier-2016-du-college-de-la-haute-autorite-de-sante-sur-l-efficience-de-la-prise-en-charge-par-l-assurance-maladie-de-la-specialite-opdivo-nivolumab-dans-le-traitement-du-melanome-avance-non-resecable-ou-metastatique?xtmc=&xtcr=5."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0325","unstructured":"Hecketsweiler C. L\u2019incroyable inflation des prix des m\u00e9dicaments. Le Monde.fr [Internet]. 2017. Disponible sur\u00a0: http:\/\/www.lemonde.fr\/economie\/article\/2017\/09\/07\/l-incroyable-inflation-des-prix-des-medicaments_5182328_3234.html."},{"key":"10.1016\/j.bulcan.2018.12.007_bib0165","unstructured":"The GoodRx Prescription Savings Blog. FDA Approves Yescarta for Non-Hodgkin Lymphoma [Internet]. 2017. Disponible sur\u00a0: https:\/\/www.goodrx.com\/blog\/fda-approves-yescarta-for-non-hodgkin-lymphoma\/."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118304077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118304077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:30:18Z","timestamp":1757791818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118304077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0007455118304077"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.12.007","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les immunoth\u00e9rapies sp\u00e9cifiques dans le traitement des cancers","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}